FreeTheAI

Pharming Group Reports Positive Phase 2 Data for Leniolisib in Rare Immune Disorders

MixedMedium impact
PHARM€0.8450 −3.43%

Pharming Group N.V. (EURONEXT:PHARM) announced positive topline results from a Phase II study evaluating leniolisib in patients with genetically identifiable primary immunodeficiencies (PIDs) accompanied by immune dysregulation. The 13-participant, single-arm trial demonstrated physical improvements, including reductions in spleen volume and positive trends in lung function over a short treatment period. Despite the trial update, shares of the company declined 3.43% to 0.845 EUR.

The clinical findings indicate that leniolisib, marketed under the brand name Joenja, may extend its therapeutic application beyond its initial approval for APDS. Genetically identifiable PIDs affect an estimated 7.5 per million people, compared to 1.5 per million for APDS. Expanding treatment into these additional conditions broadens the overall potential patient population for the therapy.

Attention now turns to November, when Pharming Group is expected to report Phase II topline data for leniolisib in common variable immunodeficiency (CVID). Given that CVID has a higher prevalence of roughly 39 per million individuals, the upcoming readout represents a key trial milestone that could shape future registrational studies.

Key points

  • Pharming Group reported positive Phase II topline trial data for leniolisib in primary immunodeficiencies with immune dysregulation.
  • The 13-patient open-label trial showed reductions in spleen size and encouraging trends in pulmonary function.
  • Targeted genetic PIDs affect roughly 7.5 per million individuals, representing a larger patient market than APDS.
  • Pharming Group expects to report Phase II trial results for leniolisib in CVID in November.
  • Pharming Group shares fell 3.43% to 0.845 EUR following the announcement.

Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org

How we writeDisclaimer

Questions and answers

What were the Phase 2 trial results for Pharming Group's leniolisib?

Pharming Group reported positive Phase II topline results showing reduced spleen volume and positive trends in lung function in 13 patients with primary immunodeficiencies featuring immune dysregulation.

When will Pharming Group report Phase 2 CVID trial data?

Pharming Group expects to release Phase II topline trial results for leniolisib in common variable immunodeficiency (CVID) in November.

How large is the addressable market for leniolisib in CVID and PIDs?

Genetic PIDs affect an estimated 7.5 people per million and CVID affects approximately 39 per million, compared to 1.5 per million for APDS.